SPECIALTY GRAND CHALLENGE article
Sec. Diabetes and Pregnancy
Gestational Diabetes Mellitus: Long-Term Consequences for the Mother and Child Grand Challenge: How to Move on Towards Secondary Prevention?
- Department of Obstetrics and Gynecology, Soroka University Medical Center (SUMC), Ben-Gurion University of the Negev (BGU), Beer-Sheva, Israel
Gestational diabetes mellitus (GDM) is defined as glucose intolerance that begins during pregnancy (1). GDM occurs when the body is no longer able to adapt to its new circumstances, and the endocrine system is unable to produce sufficient insulin (2). GDM affects approximately 4-10% of pregnancies in the United States annually, depending on the characteristics of the population studied, and the diagnostics utilized (3, 4). It is clear that GDM is associated with adverse immediate pregnancy outcomes. These include an increased risk for gestational hypertension, preeclampsia and cesarean section (5). Additionally, fetal complications of GDM pregnancies include increased risk of macrosomia, shoulder dystocia, neonatal hypoglycemia and hyperbilirubinemia, and operative delivery (6).
However, recent research has shown that GDM continues to affect maternal and neonatal health long after the index pregnancy.
Long-Term Consequences to the Mother
Type 2 Diabetes Mellitus (T2DM)
Women with previous GDM have been shown to exhibit substantially increased risk for the development of T2DM, (7–10). A systematic review of 20 collated research studies found that GDM patients have an approximately 7-fold increase in risk of T2DM compared to no-GDM pregnancies (7). A population-based study found that 18.9% of women with previous GDM developed T2DM within 9 years after the index pregnancy; the rate was only 2% in the comparison group of women without GDM (2.0%). The rate of T2DM development increased in the first nine months postpartum, and 3.7% of patients had developed T2DM within nine months (8).
GDM increase postpartum risk of metabolic syndrome and cardiovascular disease. Metabolic syndrome is characterized by several risk factors, including central obesity, hypertension, insulin resistance, and dyslipidemia (11). Several studies have demonstrated an association between GDM and risk of subsequent maternal cardiovascular morbidity (12–14). Women with previous GDM have also an increased risk of cardiovascular risk factors such as hypertension, dyslipidemia, obesity, and metabolic syndrome (14–16). Specifically, GDM was found to be an independent risk factor for long-term maternal risk of noninvasive diagnostic procedures, simple cardiovascular events, and cardiovascular hospitalizations (12). Bo et al. followed women with GDM 6.5 years postpartum, and found they had significantly higher levels of vascular endothelial dysfunction markers than women with normal pregnancies. The authors concluded that GDM mothers experience a higher risk of future cardiovascular diseases than do normoglycemic mothers (17). Moreover, another study reported that when slight glucose intolerance (regardless of overt GDM) exists, a dose-response effect can be seen between glucose level during pregnancy and postpartum atherosclerotic morbidity (18).
Women with a history GDM might have a higher future long-term risk for the development of malignancies: hospitalizations due to malignancies years after postpartum were increased in women with GDM. A significant association was documented between GDM and risk of developing ovarian, endometrial, and/or breast cancer (19). Other studies showed a positive association between GDM and higher glucose levels during pregnancy and the risk of breast cancer (20, 21). Perrin et al., with a follow-up of 28–40 years, documented five cases of pancreatic cancer in women with GDM history, and an adjusted relative risk of 7.1 was documented (21). Similarly, another study indicated that GDM women were more likely to be diagnosed with pancreatic cancer (22).
GDM has also been reported to be a significant risk factor for long-term ophthalmic morbidity: Women with GDM history had significantly higher incidence of ophthalmic morbidity (e.g., glaucoma, diabetic retinopathy, retinal detachment) compared to controls (23). A significant number of women who experience GDM will develop T2DM years following postpartum, and as such retinopathy will effect up to 20% of them (24).
GDM seems like a significant risk factor for long-term renal morbidity. The most common future renal diagnoses were hypertensive renal disease without renal failure, hypertensive renal disease with renal failure, chronic renal failure, and end-stage renal disease (25).
Long-Term Consequences to the Offspring
Maternal diabetic intrauterine environment is strongly associated with T2DM development in the offspring. In a multiethnic population 30.4% of youth with T2DM had been exposed to maternal diabetes, compared to 6.3% of nondiabetic youth controls (26). In another cohort of obese adolescents 31.1% of obese children with normal glucose tolerance who had been exposed to GDM developed impaired glucose tolerance/diabetes over a relatively short follow-up period (avg. < 3 years). The results indicate that offspring of mothers with GDM history have at least 5 times greater risk of developing impaired glucose tolerance than those not exposed to gestational diabetes (27). Similarly, 21% of youth with either T2DM or pre-diabetes (impaired glucose tolerance or impaired fasting glucose) were offspring of women with diet-treated GDM, compared to 4% of women from the background population (28). The Pima have exceptionally high rates of obesity and T2DM. T2DM prevalence in Pima children is up to 6 times greater in those with diabetic or prediabetic mothers; T2DM in childhood and adolescence occurs almost exclusively among the offspring of diabetic and prediabetic mothers (29). There is evidence that the higher frequency of diabetes and obesity in the offspring of diabetic Pima women is not only due to genetic susceptibility to obesity and diabetes. Studies including sibling pairs with one sibling born before the onset of maternal diabetes, and one after, have brought interesting data: Being born after the mother developed diabetes led to a significantly higher risk of diabetes in offspring (30, 31).
The relationship between childhood elevated BMI and maternal diabetes was examined in a comprehensive metaanalysis, and a strong relationship was found between prenatal exposure to maternal diabetes and increased childhood BMI (32). Abokaf et al. found that the rate of obesity following in-utero exposure to GDM was as high as 4.9% following diet controlled GDM and 7.8% following GDM uncontrolled by diet. The rates of obesity in offspring of non-GDM women was as low as 1.8% (P<0.001) (33). The association between GDM and obesity of the offspring was established in other cohorts (34–36) and reviews (37).
A recent population-based study found a significant association between exposure to GDM and the risk for long-term endocrine morbidity in the offspring (33). During the study period 231,271 deliveries met the inclusion criteria, of which 12,642 deliveries (5.4%) were diagnosed with GDM. The incidence rate of diabetes mellitus, overweight and obesity among children was significantly higher in the GDM group. The rates of hypothyroidism were comparable between the groups. Using a GEE model, controlling for confounders such as maternal age, follow up-time, obesity and birthweight, in-utero exposure to diet controlled GDM (adjusted OR = 2.1; 95% CI 1.7–2.7; P < 0.001) and especially to GDM uncontrolled by diet (adjusted OR = 3.1; 95% CI 2.2–4.4, P < 0.001) were found as risk factors for long-term endocrine disease during childhood including diabetes overweight and obesity (33).
A significant association was recently noted between GDM and the rate of cardiovascular hospitalizations of the offspring (38). Nevertheless, the risk was extremely low: 0.97% for GDM A2 vs. 0.57% for GDM A1 vs. 0.33% for no GDM, respectively; p < 0.001.
Neurodevelopmental Outcome and Neuropsychiatric Morbidity
Previous literature suggests convincing evidence that offspring of diabetic mothers are at risk of impaired neurodevelopmental outcome (39). A population-based study conducted in southern Israel investigated long-term neuropsychiatric morbidities in offspring exposed to GDM. Neuropsychiatric illnesses included in this study were autistic spectrum disorder, eating disorders, cerebral palsy, obstructive sleep apnea, epilepsy, and infantile spasms (40). During the study period 231,271 deliveries met the inclusion criteria; 5.4% of the births were to mothers diagnosed with GDM (n = 12,642), of these 4.3% had GDM type A1 (n = 10,076) and 1.1% had GDM type A2 (n = 2566). During the follow-up period, a significant linear association was noted between the severity of the gestational diabetes (no gestational diabetes, gestational diabetes mellitus A1, gestational diabetes mellitus A2) and neuropsychiatric disease of the offspring (1.02% vs 1.36% vs 1.68%, respectively, P <.001). Additionally, children exposed to GDM who developed neuropsychiatric disease did so at a younger age than their unexposed counterparts: A Kaplan-Meier curve demonstrated that children born to women with GDM had higher cumulative incidence of neuropsychiatric morbidity. Using a generalized estimating equation multivariable logistic regression model, controlling for time-to-event, maternal age, gestational age at delivery, maternal obesity, maternal preeclampsia and fertility treatments, maternal GDM was found to be an independent risk factor for long-term neuropsychiatric disease of the offspring.
A recent study investigated whether children born to mothers with GDM are at increased risk to develop pediatric ophthalmic morbidity. Offspring of patients with GDM treated by medication had a higher cumulative incidence of ophthalmic morbidity when compared to the other groups (Kaplan-Meier log rank test p = 0.038). GDM treated by medication was found to be an independent risk factor for long-term ophthalmic morbidity, in a cox multivariable model (adjusted HR: 1.5, 95% CI: 1.05-2.1, p = 0.025). Authors concluded that GDM treated by medication was associated with an increased risk for long-term pediatric ophthalmic morbidity (41).
Worldwide, the prevalence of GDM in women of childbearing age has been on the rise (42).
As was reviewed in this article, solid data exists regarding the association between gestational diabetes mellitus (GDM) and long-term maternal cardiovascular disease. The rate of cardiovascular disease following GDM is about 9%. Likewise, several studies found an association between GDM and other maternal long-term complications such as renal, ophthalmic and even oncological diseases. Recent studies found an association between GDM and long-term complications to the offspring. While the risk for most morbidities is relatively low, although significant, the risk for endocrine morbidity of the offspring can reach 8%.
The grand challenges are how to use this data to move towards secondary prevention. Secondary prevention involves population at risk, i.e. women with GDM and their offspring that has not yet developed clinical signs and symptoms of the disease. Prevention programs should focus on secondary prevention of cardiovascular disease in patients following GDM, which deserve post-partum follow-up visits. This knowledge had recently led the International Federation of Gynecology and Obstetrics (FIGO) to recommend follow-up of all women with GDM 6–12 weeks after birth, and periodically thereafter, with screening for overt diabetes and cardiovascular risk factors (42). In an attempt to achieve consensus on uniform diagnostic criteria from this diversity and in response to the HAPO data (43) the International Association of Diabetes in Pregnancy Study Groups (IADPSG) convened a consensus panel who developed outcome-based criteria for the diagnosis of GDM (44). The panel considered a variety of possible diagnostic strategies, which were adopted by a variety of professional health-care bodies. Nevertheless, the FIGO guidelines (42) were recommended regardless of the definitions used for GDM.
In addition, secondary prevention should focus on offspring of GDM mothers for the prevention of obesity and diabetes of the offspring.
The author confirms being the sole contributor of this work and has approved it for publication.
Conflict of Interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
2. Sella T, Chodick G, Barchana M, Heymann AD, Porath A, Kokia E, et al. Gestational diabetes and risk of incident primary cancer: a large historical cohort study in Israel. Cancer Causes Control (2011) 22(11):1513–20. doi: 10.1007/s10552-011-9825-5
4. Chen Y, Quick WW, Yang W, Zhang Y, Baldwin A, Moran J, et al. Cost of gestational diabetes mellitus in the United States in 2007. Popul Health Manag (2009) 12(3):165–74. doi: 10.1089/pop.2009.12303
5. Dodd JM, Crowther CA, Antoniou G, Baghurst P, Robinson JS. Screening for gestational diabetes: the effect of varying blood glucose definitions in the prediction of adverse maternal and infant health outcomes. Aust N Z J Obstet Gynaecol (2007) 47:307–12. doi: 10.1111/j.1479-828X.2007.00743.x
6. Karmon A, Levy A, Holcberg G, Wiznitzer A, Mazor M, Sheiner E. Decreased perinatal mortality among women with diet-controlled gestational diabetes mellitus. Int J Gynecol Obstet (2009) 104(3):199–202. doi: 10.1016/j.ijgo.2008.09.016
7. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet (2009) 373:1773–9. doi: 10.1016/S0140-6736(09)60731-5
9. Lauenborg J, Hansen T, Jensen DM, Vestergaard H, Mølsted-Pedersen L, Hornnes P, et al. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care (2004) 27:1194–9. doi: 10.2337/diacare.27.5.1194
12. Kessous R, Shoham-Vardi I, Pariente G, Sherf M, Sheiner E. An association between gestational diabetes mellitus and long-term maternal cardiovascular morbidity. Heart (2013) 99:1118–21. doi: 10.1136/heartjnl-2013-303945
13. Goueslard K, Cottenet J, Mariet A-S, Giroud M, Cottin Y, Petit JM, et al. Early cardiovascular events in women with a history of gestational diabetes mellitus. Cardiovasc Diabetol (2016) 15:15. doi: 10.1186/s12933-016-0338-0
14. Carr DB, Utzschneider KM, Hull RL, Tong J, Wallace TM, Kodama K, et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care (2006) 29:2078–83. doi: 10.2337/dc05-2482
15. Lauenborg J, Mathiesen E, Hansen T, Glümer C, Jørgensen T, Borch-Johnsen K, et al. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab (2005) 90:4004–10. doi: 10.1210/jc.2004-1713
16. Di Cianni G, Lencioni C, Volpe L, Ghio A, Cuccuru I, Pellegrini G, et al. C–reactive protein and metabolic syndrome in women with previous gestational diabetes. Diabetes Metab Res Rev (2007) 23:135–40. doi: 10.1002/dmrr.661
17. Bo S, Valpreda S, Menato G, Bardelli C, Botto C, Gambino R, et al. Should we consider gestational diabetes a vascular risk factor? Atherosclerosis (2007) 194:e72–9. doi: 10.1016/j.atherosclerosis.2006.09.017
18. Charach R, Wolak T, Shoham-Vardi I, Sergienko R, Sheiner E. Can slight glucose intolerance during pregnancy predict future maternal atherosclerotic morbidity? Diabet Med (2016) 33:920–5. doi: 10.1111/dme.13036
19. Fuchs O, Sheiner E, Meirovitz M, Davidson E, Sergienko R, Kessous R. The association between a history of gestational diabetes mellitus and future risk for female malignancies. Arch Gynecol Obstet (2017) 295(3):731–6. doi: 10.1007/s00404-016-4275-7
21. Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, et al. Gestational diabetes and the risk of breast cancer among women in the Jerusalem Perinatal Study. Breast Cancer Res Treat (2008) 108(1):129–35. doi: 10.1007/s10549-007-9585-9
22. Perrin M, Terry M, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, et al. Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med (2007) 5:25. doi: 10.1186/1741-7015-5-25
23. Beharier O, Sergienko R, Kessous R, Szaingurten-Solodkin I, Walfisch A, Shusterman E, et al. Gestational diabetes mellitus is a significant risk factor for long-term ophthalmic morbidity. Arch Gynecol Obstet (2017) 295:1477–82. doi: 10.1007/s00404-017-4362-4
24. Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, Vander Beek BL, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care (2017) 40:412–8. doi: 10.2337/dc16-2641
25. Beharier O, Shoham-Vardi I, Pariente G, Sergienko R, Kessous R, Baumfeld Y, et al. Gestational diabetes mellitus is a significant risk factor for long-term maternal renal disease. J Clin Endocrinol Metab (2015) 100:1412–6. doi: 10.1210/jc.2014-4474
26. Dabelea D, Mayer-Davis EJ, Lamichhane AP, D’Agostino RB Jr, Liese AD, Vehik KS, et al. Association of Intrauterine Exposure to Maternal Diabetes and Obesity With Type 2 Diabetes in Youth: The SEARCH Case-Control Study. Diabetes Care (2008) 31(7):1422–6. doi: 10.2337/dc07-2417
27. Holder T, Giannini C, Santoro N, Pierpont B, Shaw M, Duran E, et al. A low disposition index in adolescent offspring of mothers with gestational diabetes: a risk marker for the development of impaired glucose tolerance in youth. Diabetologia (2014) 57(11):2413–20. doi: 10.1007/s00125-014-3345-2
28. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care (2008) 31:340–6. doi: 10.2337/dc07-1596
29. Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J. Pediatr Endocrinol Metab (2001) 14:1085e91. doi: 10.1515/jpem-2001-0803
31. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes (2000) 49:2208e11. doi: 10.2337/diabetes.49.12.2208
32. Philipps LH, Santhakumaran S, Gale C, Prior E, Logan KM, Hyde MJ, et al. The diabetic pregnancy and offspring BMI in childhood: a systematic review and meta-analysis. Diabetologia (2011) 54(8):1957–66. doi: 10.1007/s00125-011-2180-y
33. Abokaf H, Shoham-Vardi I, Sergienko R, Landau D, Sheiner E. In utero exposure to gestational diabetes mellitus and long term endocrine morbidity of the offspring. Diabetes Res Clin Pract (2018) 144:231–5. doi: 10.1016/j.diabres.2018.09.003
35. Zhu Y, Olsen SF, Mendola P, Yeung EH, Vaag A, Bowers K, et al. Growth and obesity through the first 7 y of life in association with levels of maternal glycemia during pregnancy: a prospective cohort study. Am J Clin Nutr (2016) 103(3):794–800. doi: 10.3945/ajcn.115.121780
36. Zhao P, Liu E, Qiao Y, Katzmarzyk PT, Chaput JP, Fogelholm M, et al. Maternal gestational diabetes and childhood obesity at age 9–11: results of a multinational study. Diabetologia (2016) 59(11):2339–48. doi: 10.1007/s00125-016-4062-9
37. Farahvar S, Walfisch A, Sheiner E. Gestational diabetes risk factors and long-term consequences for both mother and offspring: a literature review. Expert Rev Endocrinol Metab (2019) 14(1):63–74. doi: 10.1080/17446651.2018.1476135
38. Leybovitz-Haleluya N, Wainstock T, Landau D, Sheiner E. Maternal gestational diabetes mellitus and the risk of subsequent pediatric cardiovascular diseases of the offspring: a population-based cohort study with up to 18 years of follow up. Acta Diabetol (2018) 55(10):1037–42. doi: 10.1007/s00592-018-1176-1
40. Nahum Sacks K, Friger M, Shoham-Vardi I, Abokaf H, Spiegel E, Sergienko R, et al. Prenatal exposure to gestational diabetes mellitus as an independent risk factor for long-term neuropsychiatric morbidity of the offspring. Am J Obstet Gynecol (2016) 215(3):380.e1–7. doi: 10.1016/j.ajog.2016.03.030
41. Walter E, Tsumi E, Wainstock T, Spiegel E, Sheiner E. Maternal gestational diabetes mellitus: is it associated with long-term pediatric ophthalmic morbidity of the offspring? J Matern Fetal Neonatal Med (2019) 32(15):2529–38. doi: 10.1080/14767058.2018.1439918
42. Sheiner E, Kapur A, Retnakaran R, Hadar E, Poon LC, McIntyre HD, et al. FIGO (International Federation of Gynecology and Obstetrics) Postpregnancy Initiative: Long-term Maternal Implications of Pregnancy Complications—Follow-up Considerations. Int J Gynecol Obstet (2019) 147:1–31. doi: 10.1002/ijgo.12926
43. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med (2008) 358(19):1991–2002. doi: 10.1056/NEJMoa0707943
44. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care (2010) 33(3):676–82. doi: 10.2337/dc09-1848
Keywords: gestational diabetes mellitus (GDM), diabetes, long-term cardiovascular disease, pregnancy, offspring, obesity, long-term morbidity
Citation: Sheiner E (2020) Gestational Diabetes Mellitus: Long-Term Consequences for the Mother and Child Grand Challenge: How to Move on Towards Secondary Prevention? Front. Clin. Diabet. Health 1:546256. doi: 10.3389/fcdhc.2020.546256
Received: 27 March 2020; Accepted: 12 October 2020;
Published: 04 November 2020.
Edited and reviewed by: Yoshifumi Saisho, Keio University, Japan
Copyright © 2020 Sheiner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eyal Sheiner, email@example.com